Anixa Biosciences, Inc. (ANIX)
2.90
-0.01
(-0.34%)
USD |
NASDAQ |
Oct 09, 16:00
2.90
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Cash from Operations (Quarterly) : -1.77M for July 31, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -1.77M |
| April 30, 2026 | -1.741M |
| January 31, 2026 | -2.61M |
| October 31, 2025 | -1.255M |
| July 31, 2025 | -1.511M |
| April 30, 2025 | -1.503M |
| January 31, 2025 | -2.904M |
| October 31, 2024 | -0.927M |
| July 31, 2024 | -2.643M |
| April 30, 2024 | -1.456M |
| January 31, 2024 | -2.309M |
| October 31, 2023 | -1.969M |
| July 31, 2023 | -1.445M |
| April 30, 2023 | -0.807M |
| January 31, 2023 | -1.988M |
| October 31, 2022 | -1.593M |
| July 31, 2022 | -1.396M |
| April 30, 2022 | -2.306M |
| January 31, 2022 | -1.197M |
| October 31, 2021 | -1.044M |
| July 31, 2021 | -1.481M |
| April 30, 2021 | -1.242M |
| January 31, 2021 | -1.170M |
| October 31, 2020 | -1.414M |
| July 31, 2020 | -1.291M |
| Date | Value |
|---|---|
| April 30, 2020 | -1.556M |
| January 31, 2020 | -1.914M |
| October 31, 2019 | -1.337M |
| July 31, 2019 | -0.6401M |
| April 30, 2019 | -1.435M |
| January 31, 2019 | -1.330M |
| October 31, 2018 | -1.021M |
| July 31, 2018 | -1.17M |
| April 30, 2018 | -0.7425M |
| January 31, 2018 | -1.34M |
| October 31, 2017 | -0.7393M |
| July 31, 2017 | -1.251M |
| April 30, 2017 | -1.076M |
| January 31, 2017 | -0.7299M |
| October 31, 2016 | -0.683M |
| July 31, 2016 | -0.8147M |
| April 30, 2016 | -1.352M |
| January 31, 2016 | -0.5324M |
| October 31, 2015 | -0.8019M |
| July 31, 2015 | -0.7085M |
| April 30, 2015 | -1.779M |
| January 31, 2015 | 4.653M |
| October 31, 2014 | -0.3621M |
| July 31, 2014 | -0.3373M |
| April 30, 2014 | -0.5078M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Mera Pharmaceuticals, Inc. | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.245M |
| Cash from Financing (Quarterly) | 1.936M |
| Free Cash Flow | -7.376M |
| Free Cash Flow Per Share (Quarterly) | -0.0518 |
| Free Cash Flow to Equity (Quarterly) | -1.76M |
| Free Cash Flow to Firm (Quarterly) | -1.77M |
| Free Cash Flow Yield | -7.59% |